A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Sponsor
Bristol-Myers Squibb
Study ID
NCT06452329
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    As prescribed by treating physician

Study Details

The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China

Key Dates

First listed
Jun 11, 2024
Start date
Feb 28, 2024
Status verified
Nov 2025
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025

Study Design

Enrollment
260 participants (actual)

Arms

  • Arm: Participants who received first-line nivolumab therapy for advanced GC/GEJC

Primary Outcome Measure

Time to progression (TTP) [ Time Frame: Up to 68 months ]

Find similar trials

Nationwide
Gastric cancer trialsOncology trialsGI oncology trials

Related Studies